Binimetinib clinical trials
Also written MEK162, Mektovi and ARRY-438162.
How each study uses binimetinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the binimetinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 Jun 2018 · MEKTOVI · NDA 210498 (FDA, Drugs@FDA)
- European Union
- 20 Sept 2018 · Mektovi · EMEA/H/C/004579 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
101 studies that test it; most in 2019 (11)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 5 |
| 2012 | 5 |
| 2013 | 10 |
| 2014 | 6 |
| 2015 | 5 |
| 2016 | 9 |
| 2017 | 7 |
| 2018 | 6 |
| 2019 | 11 |
| 2020 | 9 |
| 2021 | 11 |
| 2022 | 5 |
| 2023 | 6 |
| 2024 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 39 · Other 62
Pfizer (21) · Array Biopharma, now a wholly owned subsidiary of Pfizer (9) · National Cancer Institute (NCI) (8) · M.D. Anderson Cancer Center (5) · Pierre Fabre Medicament (5) · University Health Network, Toronto (4) · Memorial Sloan Kettering Cancer Center (4) · H. Lee Moffitt Cancer Center and Research Institute (3)
Often tested with
Tested in the same studies.
Encorafenib (38) · Nivolumab (8) · Palbociclib (7) · Pembrolizumab (6) · Dabrafenib (4) · Trametinib (4) · Ribociclib (4) · Alpelisib (3)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 9, 2 in phase 3
Studies that test binimetinib, phase 3 first.
- Mar 2027Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.Phase 3 · Pierre Fabre Medicament
- Jun 2027Personalized Medicine for Advanced Biliary Cancer PatientsPhase 3 · UNICANCER
- Nov 2026MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)Phase 1/2 · Memorial Sloan Kettering Cancer Center
- Dec 2026Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF MutationsPhase 2 · University Health Network, Toronto
- Jan 2027Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast CancerPhase 2 · Laura Huppert, MD, BA
- Feb 2027Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System MetastasesPhase 2 · M.D. Anderson Cancer Center
- Apr 2027MEKTOVI® for the Treatment of Pediatric Adamantinomatous CraniopharyngiomaPhase 2 · Nationwide Children's Hospital
- May 2027Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant MelanomaPhase 2 · University of California, San Francisco
- Jun 2027A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesPhase 2 · SWOG Cancer Research Network
Studies
Open first, then newest update. How each study uses binimetinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 101
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377Written as Binimetinib
- Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic CancerRecruitingPhase 2National Cancer Center, JapanNCT06159478Written as Binimetinib 15 MG
- The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical TrialsRecruitingPhase 4PfizerNCT05203172Written as Binimetinib
- Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and VariantRecruitingPhase 2National Cancer Institute (NCI)NCT04322383Written as binimetinib
- A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesRecruitingPhase 2SWOG Cancer Research NetworkNCT04511013Written as Binimetinib
- Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant MelanomaRecruitingPhase 2University of California, San FranciscoNCT04598009Written as Binimetinib
- Personalized Medicine for Advanced Biliary Cancer PatientsRecruitingPhase 3UNICANCERNCT05615818Written as Binimetinib
- Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System MetastasesRecruitingPhase 2M.D. Anderson Cancer CenterNCT05026983Written as Binimetinib
- MEKTOVI® for the Treatment of Pediatric Adamantinomatous CraniopharyngiomaRecruitingPhase 2Nationwide Children's HospitalNCT05286788Written as Binimetinib Oral Tablet [Mektovi]
- Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATERecruitingPhase 1/2Peter MacCallum Cancer Centre, AustraliaNCT04720768Written as Binimetinib
- Melanoma Metastasized to the Brain and SteroidsRecruitingPhase 2Inge Marie SvaneNCT03563729Written as Binimetinib
- Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT04439344Written as Binimetinib
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Binimetinib
- Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT05564403Written as Binimetinib
- MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal CancerCompletedPhase 1City of Hope Medical CenterNCT02041481Written as MEK inhibitor MEK162
- Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node InvolvementTerminatedPhase 2ECOG-ACRIN Cancer Research GroupNCT04221438Written as Binimetinib
- A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaActive, not recruitingPhase 3PfizerNCT04657991Written as Binimetinib
- Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment TrialActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05554367Written as Binimetinib
- ENCOrafenib With Binimetinib in bRAF NSCLCActive, not recruitingPhase 2Intergroupe Francophone de Cancerologie ThoraciqueNCT04526782Written as Binimetinib 15 MG
- Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal CancerCompletedPhase 2Pierre Fabre MedicamentNCT03693170Written as Binimetinib
See all 101 studies that test binimetinib →
Given beside what is tested · 16 — binimetinib is usual care or a partner of the new treatment
- Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast CancerRecruitingPhase 1National Cancer Institute (NCI)NCT05111561Written as Binimetinib
- A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid TumorsRecruitingPhase 1Pierre Fabre MedicamentNCT04913285Written as KIN-2787 and binimetinib
- Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsRecruitingPhase 1/2IDEAYA BiosciencesNCT03947385Written as Binimetinib
- Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic MelanomaRecruitingPhase 1Rina PlattnerNCT04903119Written as Binimetinib
- A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.Active, not recruitingPhase 1PfizerNCT05355701Written as binimetinib
- Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain MetastasisActive, not recruitingPhase 2UNICANCERNCT04074096Written as Binimetinib Oral Tablet
- PF-07284892 in Participants With Advanced Solid TumorsTerminatedPhase 1PfizerNCT04800822Written as binimetinib
- Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid TumorsTerminatedPhase 1Deciphera Pharmaceuticals, LLCNCT04892017Written as Binimetinib
- A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain InvolvementTerminatedPhase 1PfizerNCT04543188Written as Binimetinib
- JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid TumorsCompletedPhase 1/2Allist Pharmaceuticals, Inc.NCT04720976Written as Binimetinib
- NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)CompletedPhase 1/2OnKure, Inc.NCT05340621Written as OKI-179 + binimetinib
- Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant CancerTerminatedPhase 1Taiho Oncology, Inc.NCT04965818Written as Futibatinib and Binimetinib
- Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose IpilimumaTerminatedPhase 1/2Jason J. Luke, MDNCT04655157Written as binimetinib
- A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid TumorsTerminatedPhase 1/2PfizerNCT03637491Written as Binimetinib
- MEK and MET Inhibition in Colorectal CancerCompletedPhase 1University of OxfordNCT02510001Written as Binimetinib
- Lorlatinib Combinations in Lung CancerStatus unknownPhase 1/2Massachusetts General HospitalNCT04292119Written as Binimetinib
Codes
What other systems call binimetinib · ClinicalTrials.gg INT006287
- MeSH (NLM) C581313binimetinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 181R97MR71BINIMETINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2049122Confirmed FDA, Wikidata
- Wikidata Q19903515binimetinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C84865BinimetinibOne source FDA
- DrugBank DB11967One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C581313 | binimetinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 181R97MR71 | BINIMETINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2049122 | — | Confirmed FDA, Wikidata |
| Wikidata | Q19903515 | binimetinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C84865 | Binimetinib | One source FDA |
| DrugBank | DB11967 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.